Clinical Trial Results:
Konsekutive Aderlass- und Peginterferon alfa-2a -Ribavirin-Standardtherapie im Vergleich zu einer Peginterferon alfa-2a-Ribavirin-Standardtherapie bei naiven Patienten mit HCV Genotyp 1 und Ferritin > 200 μg/l
Summary
|
|
EudraCT number |
2006-000504-17 |
Trial protocol |
DE |
Global completion date |
30 Nov 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
05 Feb 2020
|
First version publication date |
05 Feb 2020
|
Other versions |
|
Summary report(s) |
FinalReportSynopsis_KAPRI_03112013 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.